Abstract

The immunoprotective components control COVID-19 disease severity, as well as long-term adaptive immunity maintenance and subsequent reinfection risk discrepancies across initial COVID-19 severity, remain unclarified. Here, we longitudinally analyzed SARS-CoV-2-specific immune effectors during the acute infection and convalescent phases of 165 patients with COVID-19 categorized by severity. We found that early and robust SARS-CoV-2-specific CD4+ and CD8+ T cell responses ameliorate disease progression and shortened hospital stay, while delayed and attenuated virus-specific CD8+ T cell responses are prominent severe COVID-19 features. Delayed antiviral antibody generation rather than titer level associates with severe outcomes. Conversely, initial COVID-19 severity imprints the long-term maintenance of SARS-CoV-2-specific adaptive immunity, demonstrating that severe convalescents exhibited more sustained virus-specific antibodies and memory T cell responses compared to mild/moderate counterparts. Moreover, initial COVID-19 severity inversely correlates with SARS-CoV-2 reinfection risk. Overall, our study unravels the complicated interaction between temporal characteristics of virus-specific T cell responses and COVID-19 severity to guide future SARS-CoV-2 wave management.

Details

Title
Initial COVID-19 severity influenced by SARS-CoV-2-specific T cells imprints T-cell memory and inversely affects reinfection
Author
Yang, Gang 1 ; Cao, Jinpeng 2 ; Qin, Jian 3 ; Mei, Xinyue 2   VIAFID ORCID Logo  ; Deng, Shidong 2 ; Xia, Yingjiao 3 ; Zhao, Jun 3 ; Wang, Junxiang 2 ; Luan, Tao 1 ; Chen, Daxiang 2 ; Huang, Peiyu 2 ; Chen, Cheng 3 ; Sun, Xi 2 ; Luo, Qi 2 ; Su, Jie 2 ; Zhang, Yunhui 3 ; Zhong, Nanshan 4 ; Wang, Zhongfang 2 

 The First People’s Hospital of Yunnan province, The Affiliated Hospital of Kunming University of Science and Technology. Department of Respiratory and Critical Care Medicine, Kunming, China (GRID:grid.414918.1); Bioland, Guangzhou National Laboratory, Guangzhou, China (GRID:grid.508040.9) (ISNI:0000 0004 9415 435X) 
 Bioland, Guangzhou National Laboratory, Guangzhou, China (GRID:grid.508040.9) (ISNI:0000 0004 9415 435X); Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072) 
 The First People’s Hospital of Yunnan province, The Affiliated Hospital of Kunming University of Science and Technology. Department of Respiratory and Critical Care Medicine, Kunming, China (GRID:grid.414918.1) 
 The First People’s Hospital of Yunnan province, The Affiliated Hospital of Kunming University of Science and Technology. Department of Respiratory and Critical Care Medicine, Kunming, China (GRID:grid.414918.1); Bioland, Guangzhou National Laboratory, Guangzhou, China (GRID:grid.508040.9) (ISNI:0000 0004 9415 435X); Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072) 
Pages
141
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3061544700
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.